PolyPid (NASDAQ:PYPD) Stock Price Down 0.6% – Time to Sell?

Shares of PolyPid Ltd. (NASDAQ:PYPD) traded down 0.6% on Tuesday . The stock traded as low as $3.34 and last traded at $3.43. 113,379 shares were traded during trading, a decline of 15% from the average session volume of 133,805 shares. The stock had previously closed at $3.45.

Analyst Upgrades and Downgrades

PYPD has been the subject of a number of analyst reports. HC Wainwright boosted their price target on PolyPid from $11.00 to $13.00 and gave the company a “buy” rating in a report on Monday, June 9th. JMP Securities lowered their price target on shares of PolyPid from $16.00 to $14.00 and set a “market outperform” rating on the stock in a report on Tuesday, June 17th. Finally, Roth Capital set a $9.00 price objective on shares of PolyPid and gave the company a “buy” rating in a report on Wednesday, June 18th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $11.80.

PolyPid Price Performance

The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 4.43. The firm has a market capitalization of $34.95 million, a PE ratio of -0.80 and a beta of 1.32. The stock has a 50-day moving average price of $3.12 and a 200 day moving average price of $2.98.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.10. Equities analysts forecast that PolyPid Ltd. will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PYPD. Rosalind Advisors Inc. boosted its holdings in PolyPid by 50.6% in the 4th quarter. Rosalind Advisors Inc. now owns 1,022,521 shares of the company’s stock worth $3,108,000 after buying an additional 343,353 shares during the last quarter. AIGH Capital Management LLC lifted its position in shares of PolyPid by 21.8% in the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after acquiring an additional 148,199 shares in the last quarter. Finally, J. Goldman & Co LP acquired a new stake in shares of PolyPid in the fourth quarter worth approximately $391,000. Institutional investors and hedge funds own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.